With Bausch + Lomb ULTRA ONE DAY contact lenses, eye care professionals can offer a solution that stands up to real-life ...

Amid swirling speculation, Bausch + Lomb ($BLCO), a global leader in the contact lens supply industry, is reportedly ...

Bausch + Lomb have refused to comment on reports that two ... The pharmaceutical company employs more than 1,500 people at their contact lens manufacturing plant in the IDA Business Park on the Cork ...

This growth has been attributed to strategic product launches such as the enVista NV intraocular lens, Blink NutriTears, and Bausch + Lomb INFUSE contact lenses. As a result, the company has raised ...

As a result I will not purchase another Bausch and Lomb product. Or only as a last resort. The optometrist that recommended the product I’ve fired. Purchased a year's supply of lenses and got a ...

As a standalone public company, Bausch now has the ability to freely allocate financial resources to innovate and develop businesses that were underfunded under its former parent company. We believe ...

Bausch + Lomb (NYSE:BLCO – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens ...

Looking ahead, Bausch + Lomb raised its revenue guidance for the full year of 2024 to a range of $4.725 * $4.825 billion, indicating a constant currency growth of approximately 16 * 18%. The company ...

Eye health firm Bausch + Lomb has received marketing approval for its full range of enVista Envy vision intraocular lenses (IOL) from the US Food and Drug Administration (FDA). Following the ...

Bausch + Lomb (NYSE:BLCO – Get Free Report)‘s stock had its “hold” rating reaffirmed by research analysts at Needham & ...

Net income attributable to Bausch + Lomb Corporation for the third quarter of 2024 was $4 million, as compared to a net loss of $84 million for the third quarter of 2023, a favorable change of $88 ...